Fiduciary Wealth Partners LLC Acquires Shares of 1,827 Johnson & Johnson (NYSE:JNJ)

Key Points

• Fiduciary Wealth Partners LLC purchased 1,827 shares of Johnson & Johnson, valued at approximately $303,000, during the first quarter, making it the firm's 25th largest holding.
• Johnson & Johnson reported earnings of $2.77 EPS for the last quarter, surpassing analysts' expectations and achieving a revenue of $23.74 billion, a 5.8% increase year-over-year.
• The company announced a quarterly dividend of $1.30 per share, set to be paid on September 9th, representing an annualized payout of $5.20 for a dividend yield of 3.1%.

Fiduciary Wealth Partners LLC bought a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,827 shares of the company's stock, valued at approximately $303,000. Johnson & Johnson accounts for about 0.3% of Fiduciary Wealth Partners LLC's holdings, making the stock its 25th biggest position.

Several other large investors also recently modified their holdings of the business. GAMMA Investing LLC grew its holdings in shares of Johnson & Johnson by 24,450.4% during the first quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock worth $1,196,596,000 after buying an additional 7,185,977 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Johnson & Johnson by 26.4% during the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after purchasing an additional 4,842,582 shares during the last quarter. Janus Henderson Group PLC boosted its position in Johnson & Johnson by 134.5% during the fourth quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company's stock valued at $1,149,536,000 after purchasing an additional 4,559,147 shares during the last quarter. Northern Trust Corp boosted its position in Johnson & Johnson by 12.3% during the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock valued at $4,456,201,000 after purchasing an additional 3,363,235 shares during the last quarter. Finally, Pacer Advisors Inc. boosted its position in Johnson & Johnson by 1,382.0% during the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock valued at $502,509,000 after purchasing an additional 2,825,626 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

JNJ has been the subject of several recent research reports. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. UBS Group raised their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Wall Street Zen cut Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Finally, The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price objective for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $174.50.

Johnson & Johnson Price Performance

Shares of JNJ traded down $0.02 during midday trading on Wednesday, hitting $170.72. The company's stock had a trading volume of 6,541,762 shares, compared to its average volume of 9,071,956. The stock has a market capitalization of $411.14 billion, a price-to-earnings ratio of 18.26, a price-to-earnings-growth ratio of 2.18 and a beta of 0.41. Johnson & Johnson has a one year low of $140.68 and a one year high of $172.18. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The company's fifty day simple moving average is $158.17 and its two-hundred day simple moving average is $157.00.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The business's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business earned $2.82 EPS. As a group, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.